BI 2536 Second Line Monotherapy in SCLC

Inclusion Criteria: * Patients with histologically or cytologically confirmed, -sensitive-relapse- SCLC defined by a relapse 60 days or more after cessation of prior first-line chemotherapy. * Patients with at least one measurable lesion, with longest diameter to be recorded as 20 mm or greater. * Life expectancy of at least three months and ECOG performance score of 2 or less and written informed consent that must be consistent with ICH-GCP Guidelines. Exclusion Criteria: * More than one prior regimen of chemotherapy, mixed small cell/large cell or combined small cell histology. * Symptomatic brain metastases or leptomeningeal disease * Patients with ascites, patients who have any other life-threatening illness or organ system dysfunction, or other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer) * Absolute neutrophil count (ANC) \<1,500/µl, platelet count \<100,000/µl, or hemoglobin \<9 mg/dl * Total bilirubin \>1.5 x ULN, aspartame amino transferase (AST) and/or alanine amino transferase (ALT) \>2.5 x ULN, or aspartate amino transferase (AST) and/or alanine amino transferase (ALT) \>5 x ULN in case of known liver metastases, serum creatinine \>2.0 mg/dl (\>176 µmol/L, SI Unit equivalent) * Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or within less than 4 half-life times of the previous drug prior to treatment with the trial drug * Radiation therapy within the past 2 weeks prior to or during treatment with the trial drug * Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents), patients with known HIV, hepatitis-B or -C infection * Known or suspected active drug or alcohol abuse * Treatment with any other investigational drug within the past 4 weeks or within less than 4 half-life times of the investigational drug * Patients with a known pre-existing coagulopathy or requiring therapeutic anticoagulation with warfarin (Coumadin ®) * Patients with neuropathy (sensory or motor) CTCAE 3